Skip to main content

Table 2 Characteristics of patients escalating vs those not escalating the dose of erenumab during the treatment

From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

Characteristic

Escalating (n = 43)

Not escalating (n = 46)

P value

Female, n (%)

37 (86.0)

41 (89.0)

0.753

Age, median (IQR)

50 (41–56)

47 (38–51)

0.122

Years of migraine history, median (IQR)

30 (20–36)

26.5 (18–37)

0.436

MMDs, median (IQR)

25 (17.5–30)

17 (11–25)

0.002

Analgesic days, median (IQR)

10 (5–28)

12 (5–19)

0.485

Triptan days, median (IQR)

6 (0–20)

0 (0–12)

0.172

Chronic migraine, n (%)

40 (93.0)

44 (95.7)

0.670

Aura, n (%)

12 (27.9)

15 (32.6)

0.651

Allodynia, n (%)

16 (37.2)

17 (37.0)

0.456

Medication overuse, n (%)

35 (81.4)

29 (63.0)

0.054

Prior preventive treatment failures, n (%)

  

0.501

 2

15 (34.9)

13 (28.3)

 

 > 2

28 (65.1)

33 (71.7)

 

Botulinum toxin failure, n (%)

22 (51.2)

22 (47.8)

0.753